Processing...
Processing...
Inmagic
®
Presto
Version 5.5 Build 151
Inmagic
®
Presto
Copyright © 2005-2021 by Lucidea Technologies Corp., Richmond BC Canada. All rights reserved.
Inmagic® and the Inmagic logo are registered trademarks of Lucidea Technologies Corp.
Unauthorized duplication or distribution is prohibited.
Other brand and product names are trademarks or registered trademarks of their respective holders. Use of any other product name does not imply endorsement of that product by Inmagic.
Third-party Licenses
Processing...
Processing...
Title
Antidépresseurs tricycliques pour le traitement des enfants et des adolescents atteints d'un trouble du spectre autistique
Subtitle
Tricyclic Antidepressants for Autism Spectrum Disorders (ASD) in Children and Adolescents
Author
Romy Hurwitz; Roger Blackmore; Philip Hazell; Katrina Williams; Susan Woolfenden
Summary
This online article, written in French, summarizes a research review conducted to determine whether tricyclic antidepressants (TCAs) can be used to treat autism symptoms, as well as challenging behaviors and co-occurring mental health conditions in autism.
The review found three studies using two TCAs (tianeptine and clomipramine) with people on the autism spectrum. Evidence of positive impacts was limited and sometimes contradictory, and side effects were reported. The article concludes that more research is required before TCAs can be recommended for use with people on the autism spectrum.
This resource is available in English, French, Portuguese, and Spanish.
Cochrane is a “global independent network of researchers, professionals, patients, carers, and people interested in health.” [Website] The network reviews evidence about health treatments.
Language
French
Subjects
Mental Health
Publisher
Cochrane
DateModified
12/30/2022 7:36 PM EST